Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,042,360 shares of the medical research company's stock after purchasing an additional 116,443 shares during the period. Thermo Fisher Scientific comprises 1.9% of Vontobel Holding Ltd.'s investment portfolio, making the stock its 13th biggest position. Vontobel Holding Ltd. owned about 0.28% of Thermo Fisher Scientific worth $518,678,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $25,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Noble Wealth Management PBC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $35,000. Finally, Cassady Schiller Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after buying an additional 33 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 1.5%

Shares of TMO stock traded up $6.28 during trading hours on Wednesday, reaching $427.75. 2,669,334 shares of the stock were exchanged, compared to its average volume of 1,969,701. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The business's fifty day moving average is $409.16 and its two-hundred day moving average is $481.67. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm has a market capitalization of $161.47 billion, a P/E ratio of 25.09, a P/E/G ratio of 2.24 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company's revenue was up .2% on a year-over-year basis. During the same period last year, the business earned $5.11 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMO. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Citigroup cut their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Argus lowered their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $604.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.